In this question-and-answer session, Michael Bond (Yale University) talks to our Senior Product Specialist, Alex Moloney PhD, about the development of LC 2, a KRAS G12C-targeting PROTAC® which is now available from Tocris.
Long-termed the “undruggable target”, RAS has recently recaptured the attention of cancer researchers. A new understanding of this target has once again reignited hopes of modulating it to tackle some of the most lethal cancers.